MD, PhD, Lead Thoracic Oncol. Unit @hospitalclinic, MedOnc, Prof. @unibarcelona, Researcher Transl Genom 🧬 Targeted Therapies @IDIBAPS, @EORTC @GECP_org, #LCSM
Sitges, España
Joined March 2017
- Tweets4.4K
- Following611
- Followers3.6K
- Likes10.2K
Noemi Reguart retweeted
💜 From visibility to power, dimensions of leadership! Inspiring voices and vibrant discussion at our ESMO Women for Oncology Forum 2026 in Madrid!
👉Sunday, 25 October, 8:30-10:00 am. Seville auditorium
ow.ly/xhKG50ZZXal
#ESMOW4O #ESMO26 @myESMO @Women4Oncology @w4o_italy
The #ESMOW4O Forum at #ESMO26 will bring together diverse perspectives to discuss designing the next generation of #OncologyLeadership and the priorities that will shape its future. #Women4Oncology
🔗 ow.ly/3RZc50ZZX9Y
Noemi Reguart retweeted
Join us at #ESMO26 for the "Advancing the Frontiers of Lung Cancer Care" symposium, where I will discuss KRAS, SCLC, immunotherapy, and ADCs with Dr. @FSkoulidis, Dr. Margarita Majem, and @TerriConneran.
Monday, October 26, 13:00 CET, Oviedo Auditorium, Hall 5, IFEMA Madrid!
Noemi Reguart retweeted
Sunvozertinib finally now available in the US - over one year since its FDA approval on July 2, 2025 for EGFR exon 20 insertion positive NSCLC after prior chemotherapy. Approval based on WU-KONG1B with RR 46%, mDOR 11.1 months.
astrazeneca-us.com/content/a…
Noemi Reguart retweeted
🔬 ¡La investigación del GECP estará presente en #ESMO26!
⭕ El Grupo Español de Cáncer de Pulmón participa en una nueva edición de uno de los principales congresos internacionales de oncología, donde compartirá nuevos avances en la investigación del #CáncerDePulmón.
👉 Nuestro Grupo presentará tres trabajos científicos en formato póster, que profundizan en aspectos clave como la exposición al radón, la respuesta al tratamiento y la enfermedad residual molecular.
🙌 Seguimos impulsando la investigación para avanzar en el conocimiento de la enfermedad y mejorar el abordaje de los pacientes.
#ESMO26 #investigacion #GECP
Noemi Reguart retweeted
Huge congrats to @Piuchagarrido for the ESMO W4O Award! Chair of the ESMO W4O Committee for years and such an inspiring role model for so many of us! And most of all, a dear dear friend! 👏👏👏 a great meaningful inspiring lecture today!
#ESMOW4O
@myESMO @Women4Oncology
Noemi Reguart retweeted
#ESMO26:@FAndreMD "As oncology evolves, so must ESMO. By helping shape the scientific agenda, building standards, strengthening people and healthcare capabilities, and delivering at a global scale, we help ensure that scientific evidence translates into better care for patients everywhere."
Noemi Reguart retweeted
Rebecca Fitzgerald, recipient of the 2026 ESMO Award, will deliver her lecture at the #ESMO26 Opening Session: Early detection meets oncology: Lessons from the oesophagus.
🔗 ow.ly/yoBs50ZXT0r
Noemi Reguart retweeted
At the #ESMO26 Opening Session, Dan A. Landau (@landau_lab), recipient of the 2026 ESMO Award for Translational Research, will deliver his lecture: A glucometer for cancer: Towards a scalable, universal residual disease measurement.
🔗 ow.ly/6evn50ZXT8C
Noemi Reguart retweeted
Explore how gender perspectives can help shape oncology science, with Pilar Garrido (@Piuchagarrido) recipient of the 2026 ESMO Women for Oncology Award, at the #ESMO26 Opening Session.
🔗 ow.ly/ghWR50ZXTeM
Noemi Reguart retweeted
Discover “Targeted cancer #immunotherapy with PD-1 blockade” with Antoni Ribas, recipient of the 2026 ESMO Lifetime Achievement Award, at the #ESMO26 Congress Opening Session.
🔗 ow.ly/pStp50ZXThk
Noemi Reguart retweeted
#ESMO President @FAndreMD explains the relevance of #ESMO26 in the information age: a Congress where the latest #CancerResearch and #ScientificInnovation converge and the #oncology community gathers to discuss and interpret new research.
#InsightsbyESMO ➡️ esmo.org/insights-by-esmo/al…
Noemi Reguart retweeted
👀 Phase 1b FURTHER trial @Cancer_Cell : 1L firmonertinib opens promising new horizons for rare #EGFR PACC mutant #NSCLC with a 68% response rate, a 16 mo mPFS, and a 47% intracranial response rate. Strong potential for this hard-to-treat EGFR mutation! @LeXiuning
Noemi Reguart retweeted
Phase III FURVENT trial of 1L firmonertinib monotherapy vs pemetrexed-based chemo does not meet primary endpoint of PFS in pts with EGFR exon 20 insertion mutant NSCLC. Press release notes OS trend and clinical benefit by RR and PFSinv. Await full data.
ir.arrivent.com/news-release…
Noemi Reguart retweeted
Phase II ETOP 18-21 AMAZE-lung trial of 2L amivantamab + lazertinib + bevacizumab after 3G TKI in EGFR NSCLC @LancetRespirMed. RR 39%. TRAEs included infusion reaction 58%, rash 50%, VTE 17% which would likely be mitigated with SQ and modern support.
thelancet.com/journals/lanre…
Noemi Reguart retweeted
Why attend the ESMO Clinical Practice Guidelines Session at #ESMO26?
“It helps you put guidelines into clinical context and make them relevant to your practice.” @DrSanjayPopat
📆Add it to your agenda: ow.ly/82oS50ZXTs0
@RuhlmannC
Noemi Reguart retweeted
ESMO Fellowship session at #ESMO26: stories, perspectives, hopes and reflections from past and present fellows. A unique source of inspiration for #YoungOncologists.
🔗 ow.ly/JJFE50ZXG1N
#ESMOFellowships #CareerDevelopment
Noemi Reguart retweeted
"The session “Beyond guidelines: Expert navigation through the grey zone of oncology practice” at #ESMO26 explores the complexities of clinical decision-making across oncology practice.
➡️ow.ly/CHhb50ZY3NB
@AndriPapakonst @AliceIndini
Noemi Reguart retweeted
Step-up dosing, monitoring after the first doses, and early recognition of cytokine release syndrome and neurological events: giving DLL3-targeted TCEs takes a trained team.
Giannis Mountzios, of Henry Dunant Hospital Center, Athens, covers the practice at our ESMO 2026 Industry Satellite Symposium, Sunday 25 October from 13:00. Come and meet him in the Salamanca Auditorium, Hall 10, and send your question ahead at grillspeakers.com. We would be glad to have you with us 🙂
@peters_solange @MartinReck2 @g_mountzios @NReguart
Add it to your calendar: lungsummit.org/calendar/sclc…
Programme and faculty: lungsummit.org/featured/sclc…
#ESMO26 #SCLC #LungCancer
Noemi Reguart retweeted
Where ICIs, DLL3-targeted TCEs and ADCs each fit in SCLC depends on when a patient relapses and what came before. Noemí Reguart speaks on sequencing at our ESMO 2026 symposium, Sunday 25 October from 13:00. Send your sequencing question ahead at grillspeakers.com. We would love to meet you in the Salamanca Auditorium, Hall 10 🙂
@peters_solange @MartinReck2 @g_mountzios @NReguart
Add it to your calendar: lungsummit.org/calendar/sclc…
Programme and faculty: lungsummit.org/featured/sclc…
#ESMO26 #SCLC #LungCancer
Noemi Reguart retweeted
DLL3-targeted TCEs, from the first results in relapsed SCLC to the trials now testing them in first line: Solange Peters takes this on at our ESMO 2026 symposium, Sunday 25 October from 13:00. Send her your question ahead at grillspeakers.com. We hope to welcome you in the Salamanca Auditorium, Hall 10, so add it to your calendar if you have not yet 🙂
@peters_solange @MartinReck2 @g_mountzios @NReguart
Add it to your calendar: lungsummit.org/calendar/sclc…
Programme and faculty: lungsummit.org/featured/sclc…
#ESMO26 #SCLC #LungCancer
